Streetbeat News

Stock Prices

MKTX

MarketAxess Holdings Inc. (NASDAQ:MKTX) reported record total credit trading volume of $303.3B in November 2023, with significant growth across all credit products. The company saw a 30% quarter-to-date volume executed over its X-Pro platform, up from 18% in Q3 2023. Key highlights include increases in average daily trading volumes (ADV) for U.S. high-grade, U.S. high-yield, emerging markets, Eurobonds, and municipal bonds compared to the previous year and October 2023. However, total rates ADV declined, and an outage at ICBC affected U.S. Treasury ADV. The preliminary variable transaction fees per million (FPM) for total credit in November was $157, slightly down from the previous year but up from October 2023.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:36 am

CVS

CVS Health has declared a quarterly dividend of $0.665 per share, marking an approximate 10% increase from the previous dividend.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:34 am

RIOT

HC Wainwright & Co. analyst Mike Colonnese has maintained a Buy rating on Riot Platforms (NASDAQ:RIOT) and increased the price target from $18 to $20.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:32 am

NIO

Nio, Inc. (NYSE:NIO) reported Q3 revenue of $2.61 billion, surpassing analysts' estimates and showing significant Y/Y and Q/Q growth in vehicle deliveries and revenue. Despite a non-GAAP loss of $0.31 per share, which was better than expected, gross margin contracted due to changes in product mix. Nio also acquired manufacturing assets from JAC for about $457 million. The company expects Q4 deliveries to increase Y/Y and projects Q4 revenue growth of 0.1% - 4%. NIO shares rose 3.55% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

December 05, 2023 | 11:25 am

PLAY

Dave & Buster's Entertainment, Inc. (NASDAQ:PLAY) is expected to report a Q3 loss of 12 cents per share compared to last year's earnings of 4 cents per share, with projected revenue of $472.25 million. The company previously reported weaker-than-expected Q2 sales. Shares fell 1.1% to $42.67. Analysts have recently adjusted their price targets and ratings: UBS (Neutral, $43), Truist Securities (Buy, $57), BMO Capital (Outperform, $55), Raymond James (Outperform, $55), and Piper Sandler (Overweight, $56).

Portfolio Pulse from Lisa Levin

December 05, 2023 | 11:08 am

ZFOX

ZeroFox has projected its Q4 revenue to be between $56M-$58M, surpassing the estimated $52.25M. The company has also raised its FY24 revenue forecast from $214M-$217M to $228.7M-$230.7M, exceeding the estimated $216M.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:06 am

FOLD

John Crowley, Executive Chairman of Amicus Therapeutics, will step down from his position effective March 4, 2024. Michael Raab, the Lead Independent Director, is set to become the new Chairman.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:05 am

HEPS

D-MARKET Electronic Services (NASDAQ:HEPS) has reported a significant increase in sales for Q3, with a total of $300.92 million. This represents a 64.19% increase from the $183.28 million reported in the same quarter of the previous year.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:05 am

ZFOX

ZeroFox Holdings (NASDAQ:ZFOX) reported Q3 losses of $(0.68) per share with sales of $65.02M, surpassing the consensus estimate of $55.97M by 16.17%. Sales increased by 51.25% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:02 am

IART

Wells Fargo analyst Larry Biegelsen upgraded Integra Lifesciences (IART) from Equal-Weight to Overweight and increased the price target from $40 to $49.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:01 am